April 3, 2013 | Insight Genetics has been selected by the National Cancer Institute (NCI) to participate in the Clinical Assay Development Program (CADP), an initiative of NCI’s Division of Cancer Treatment and Diagnosis that aims to move promising assays from the research lab into clinical trials. NCI—through the CADP—will support Insight Genetics by providing services of two CLIA-certified labs that will further validate the assay, access to clinical samples, subject matter expertise, and statistical consultation. This collaboration is the continuation of a successful relationship between NCI and Insight Genetics. In the last three years the molecular diagnostics company has been awarded four contracts from NCI for the development of companion diagnostics. Insight Genetics [PDF]